Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollar, A; Saletti, P; Roth, Arnaud; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V; Herrmann, R

doi:10.1093/annonc/mdv011

Scientific article

English

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Published inAnnals of oncology, vol. 26, no. 4, p. 709-714

Publication date2015

Abstract

Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after completing first-line chemotherapy.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Groupe Roth Arnaud (oncologie) (285)

Citation (ISO format)

KOEBERLE, D et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). In: Annals of oncology, 2015, vol. 26, n° 4, p. 709–714. doi: 10.1093/annonc/mdv011

Article (Published version)

Identifiers

PID : unige:55627
DOI : 10.1093/annonc/mdv011
PMID : 25605741

Journal ISSN0923-7534

602views

1downloads

Creation16/04/2015 11:06:00

First validation16/04/2015 11:06:00

Update14/03/2023 23:12:08

Status update14/03/2023 23:12:07

Last indexation30/10/2024 23:58:52

Archive ouverte UNIGE

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after completing first-line chemotherapy.

Technical informations